Alkem Laboratories Limited has successfully completed an unannounced inspection by the US FDA at its Contract Research Organization (CRO) facility located in Taloja, Maharashtra. The inspection, conducted on May 8, 2026, concluded with no regulatory observations. The company confirmed that no Form 483 was issued, signaling a positive outcome for the site’s quality and compliance standards.
Inspection Outcome
On May 8, 2026, the US Food and Drug Administration (US FDA) carried out an unannounced inspection at the Alkem Laboratories CRO facility in Taloja, Maharashtra. Following the conclusion of the visit, the company officially reported that no Form 483 was issued. A Form 483 is typically issued by FDA investigators when they observe conditions that may constitute violations of the Food Drug and Cosmetic Act and related acts.
Significance for the Facility
The absence of any formal observations following the inspection underscores the facility’s commitment to maintaining rigorous quality control and operational standards. As the site continues to support critical research operations, this positive result serves as a reinforcement of the company’s ongoing compliance and operational readiness within its research and development ecosystem.
Source: BSE
